Clinical trials are the basis for finding more effective treatments to improve patient quality of life and survival. Through the network of CLCNJ liver specialists, patients have a better opportunity to participate in clinical trials for multiple forms of hepatitis, reversal of liver damage (fibrosis/cirrhosis), liver cancer, and post transplant anti-rejection drugs.

Efficacy and Safety Study of PEG-Interferon (IFN) Lambda (PEG-rIL-29) Plus Ribavirin to Treat Chronic Hepatitis C Virus Infection (EMERGE)
http://clinicaltrials.gov/ct2/show/NCT01001754

SonoVue®-Enhanced Ultrasound (US) Versus Unenhanced US for Focal Liver Lesion Characterization
http://clinicaltrials.gov/ct2/show/NCT00829413

Autologous prime-boost anti-tumor vaccination in patients with hepatoma or metastatic cancers (pancreas, neuroendocrine, gastric, colon, breast) to the cancer in the liver
http://clinicaltrials.gov/ct2/show/NCT00553683

Sorafenib pre-treatment in patients undergoing Hepatic Arterial Chemo-Embolization (HACE) for unresectable hepatoma to increase tumor kill.
http://clinicaltrials.gov/ct2/show/NCT00949182

A Multicenter, Randomized, Double-Blind, Phase 3 Study of Ramucirumab (IMC-1121B) Drug Product and Best Supportive Care (BSC) Versus Placebo and BSC as Second-Line Treatment in Patients With Hepatocellular Carcinoma Following First-Line Therapy With Sorafenib
http://clinicaltrials.gov/ct2/show/NCT01140347 (opening soon)

Phase III Randomized Study of Sorafenib Plus Doxorubicin Versus Sorafenib in Patients with Advanced Hepatocellular Carcinoma (HCC)
http://clinicaltrials.gov/ct2/show/NCT01004978